AlphAIAlphAI — Financial news for AI agents
tradingview.comAUG 213 min read$CLX

Is Clorox Stock Worth Buying as GOJO Growth Meets Margin Pressure?

Clorox (CLX) reports Q4 net sales of $1.95B, up 2% YoY, with GOJO contributing 10 percentage points. Fiscal 2027 sales expected to rise 13-14%, with adjusted EPS at $5.70-$6.00. Gross margins declined due to inflation and higher costs. Organic sales growth is muted, with ERP comparisons aiding growth. CLX trades at 17.9X forward earnings, below its sub-industry multiple.

Original reporting
tradingview.com
Published Aug 21, 2026, 5:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 10:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Is Clorox Stock Worth Buying as GOJO Growth Meets Margin Pressure? — source image
Source · tradingview.com
Decision brief

The 30-second read

$CLXNeutralMed
01

Why it matters

The guidance highlights a 13‑14% sales increase and 3‑8% EPS growth, but gross margin is expected to stay near 42%, indicating pressure on profitability.

02

Market read

Clorox's guidance may shape expectations for the broader consumer‑staples sector, especially regarding margin trends.

03

What to watch

Potential cost‑saving synergies from ERP investments and inflation‑hedging strategies are not fully quantified.

Relevance 8/10Novelty 8/10Timing: post‑earnings guidance release

Background

Clorox recently acquired GOJO, expanding its health‑and‑hygiene portfolio, and now provides updated guidance for fiscal 2027.

Company-level read

Ticker impact

$CLXNeutralMedium confidence
Context

Clorox disclosed Q4 fiscal 2026 results and provided fiscal 2027 sales and earnings guidance, including the impact of the GOJO acquisition.

Expected impact

Potential modest downside or flat price action as investors weigh growth versus margin concerns.

Evidence & confidence

Guidance is new but does not signal a major earnings beat; margin compression may limit upside.

Market effects

Sector

Consumer staples face mixed demand; Clorox's guidance may influence peers like PG and CHD.

Regional

U.S. consumer‑staples sector sentiment could be modestly affected.

Global

Limited; primarily U.S. market focus.

Counterpoint

What could challenge this read

Despite margin pressure, the GOJO acquisition could unlock longer‑term growth if integration succeeds.

Key entities

  • Company
    The Clorox Company

    US consumer‑staples firm (ticker CLX) reporting earnings and guidance.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 17
$CLXMedAI 8/10

Clorox stock hits 52-week low at 84.69 USD

Clorox (CLX) stock hit a 52-week low of $84.74, down 31.51% over the past year. Despite this, InvestingPro suggests it's undervalued with a 5.89% dividend yield. Q4 earnings per share were $1.66, missing estimates. UBS raised its price target to $105, maintaining a Neutral rating. Goldman Sachs and Morgan Stanley reported on broader consumer staples trends.

investing.com2 min
SEP 3
$CLXMed

Can Cost Savings Offset Inflation & Protect Clorox's Margins?

Clorox (CLX) reported a 520 basis point gross margin contraction in Q4 fiscal 2026 due to inflation and mix challenges. The company is focusing on cost savings and productivity initiatives to offset inflationary pressures, but expects margins to remain pressured in fiscal 2027. CLX shares have risen 5.2% in the past three months, with a forward P/E of 15.97X.

finance.yahoo.com2 min
AUG 21
$CLXMedAI 8/10

How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook

Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.

tradingview.com3 min
AUG 14
$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

yahoo.com6 min
AUG 11
$CLXMedAI 8/10

Clorox (CLX) Q4 2026 Earnings Call Transcript

Clorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.

fool.com6 min
AUG 6
$CLXMed

The Clorox Company Q4 2026 Earnings Call Summary

Clorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.

yahoo.com7 min